Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immune Response treats first patient in phase Ib colon cancer trial

Sep. 23, 1998

Endorex receives Japanese patent for ImmTher

Sep. 23, 1998

Cell Genesys announces positive phase I/II results using GVAX vaccine for prostate cancer

Sep. 22, 1998

IL-4(38-37)-PE38KDEL treatment results in complete regression of human glioblastoma tumors

Sep. 21, 1998

York Medical's DiaCIM will be administered to cancer patients

Sep. 18, 1998

Techniclone submits phase II TNT protocol to FDA

Sep. 18, 1998

Maxim enters collaborative agreement with BioNative

Sep. 15, 1998

Imutec reports positive phase I/II results for Virulizin

Sep. 7, 1998

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...